Brainstorm Cell Therapeutics Inc
BCLI1.170USD
0.0000.00%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
9.26M시가총액
손실P/E TTM
자세한 내용은 Brainstorm Cell Therapeutics Inc 회사
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Brainstorm Cell Therapeutics Inc 정보
종목 코드 BCLI
회사 이름Brainstorm Cell Therapeutics Inc
상장일May 28, 2003
CEOMr. Chaim Lebovits
직원 수27
유형Ordinary Share
회계 연도 종료May 28
주소1325 Avenue Of Americas
도시NEW YORK
증권 거래소US 'Other OTC' and Grey Market
국가United States of America
우편 번호10019
전화12014880460
웹사이트https://brainstorm-cell.com/
종목 코드 BCLI
상장일May 28, 2003
CEOMr. Chaim Lebovits
Brainstorm Cell Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: 13 hours ago
마지막 업데이트: 13 hours ago
주주
주주 유형
주주
주주
비율
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
기타
93.13%
주주
주주
비율
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
기타
93.13%
주주 유형
주주
비율
Individual Investor
8.44%
Holding Company
1.21%
Investment Advisor
0.02%
기타
90.33%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
81
2.42K
0.02%
-1.20M
2025Q3
92
137.97K
1.25%
-1.09M
2025Q2
115
2.33M
29.32%
+762.13K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Ruck (Matthew J)
275.84K
2.5%
+275.84K
--
Nov 13, 2024
Lebovits Chaim
200.96K
1.82%
--
--
Apr 01, 2025
ACC International Holdings, Ltd.
133.39K
1.21%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
0.72%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.62%
--
--
Apr 01, 2025
Hartounian (Hartoun)
52.00K
0.47%
--
--
Apr 01, 2025
Patlis (Alla)
44.35K
0.4%
+40.00K
+919.54%
Jan 01, 2025
Lindborg (Stacy R)
44.15K
0.4%
--
--
Apr 01, 2025
Frenkel (Jacob A.)
43.78K
0.4%
--
--
Apr 01, 2025
Arbel (Irit)
41.05K
0.37%
--
--
Apr 01, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
날짜
배당락일
유형
비율
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
